Margaret E. Gatti-Mays

  • Citations Per Year
Learn More
This phase II trial evaluated clinical markers of efficacy and safety of exemestane in postmenopausal women at increased risk for breast cancer. Postmenopausal women (n = 42) at risk for invasive breast cancer received 25 mg exemestane daily for 2 years along with calcium and vitamin D. The primary outcome was change in mammographic density (MD) after one(More)
Castleman disease (CD), also known as angiofollicular lymph node hyperplasia and giant lymph node hyperplasia, was first described in 1956 by Dr. Benjamin Castleman as localized mediastinal lymph node proliferation. Nodal hyperplasia has been described as hyaline vascular (80–90%), plasma cell (10–20%), and mixed.1 CD is a rare disease with no racial or sex(More)
Breast tumors from young women under the age of 40 account for approximately 7% of cases and have a poor prognosis independent of established prognostic factors. We evaluated the patient population served by the Military Health System, where a disproportionate number of breast cancer cases in young women are seen and treated in a single universal coverage(More)
Toxoplasma gondii is a ubiquitous intracellular parasite with an estimated seroprevalence of 22.5% in US residents aged 12 and older. Seroprevalence reaches 95% in some low-altitude countries with hot, humid climates. Although seroprevalence is relatively common, invasive toxoplasmosis involving the central nervous system (CNS), lung, liver and myocardium(More)
  • 1